# The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCT

> **NCT07450313** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 20 (estimated)

## Conditions studied

- HSCT

## Interventions

- **DRUG:** Luspatercept

## Key facts

- **NCT ID:** NCT07450313
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-14
- **Primary completion:** 2027-06-14
- **Final completion:** 2027-06-14
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07450313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07450313, "The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07450313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*